Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C66982
http://purl.obolibrary.org/obo/NCIT_C66982
|
|---|---|
| Preferred Name | Elotuzumab |
| Definitions |
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells. |
|---|---|
| prefLabel | Elotuzumab
|
| label | Elotuzumab
|
| PDQ_Closed_Trial_Search_ID | 532249
|
| code | C66982
|
| Has_Target | |
| prefixIRI | NCIT:C66982
|
| in_subset |
See more
See less
|
| Display_Name | Elotuzumab
|
| Preferred_Name | Elotuzumab
|
| FDA_UNII_Code | 1351PE5UGS
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Elotuzumab
|
| CAS_Registry | 915296-00-3
|
| NCI_Drug_Dictionary_ID | 532249
|
| Legacy Concept Name | Anti-CS1_Monoclonal_Antibody_HuLuc63
|
| type | |
| ALT_DEFINITION | A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 532249
|
| Accepted_Therapeutic_Use_For | multiple myeloma (MM)
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1832049
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |